banner
Inquiry

Cat. No.: X22-05-ZQ302

dA-Aai

Synonym: 127191-86-0; dA-Aai; 12-[9-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]imino-14-methoxy-3,5-dioxa-10-azapentacyclo[9.7.1.02,6.08,19.013,18]nonadeca-1,6,8,11(19),13(18),14,16-heptaen-9-ol

  • CAS Number: 127191-86-0
  • Compound CID: 124428
img
Product Size
5 mg; 20 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
dA-Aai participates in the processes that lead to renal damage. Aristololactam I directly injures renal proximal tubule cells, and the cytotoxic effects of these molecules are mediated through the induction of apoptosis in a caspase-3-dependent pathway. This product can be used for content determination, identification, and pharmacological experiments, etc.
Molecular Weight
542.508
Molecular Formula
C27H22N6O7
Form
Solid
Purity
≥98%, determined by HPLC.
Identity
Confirmed by MS and NMR.
Applications
dA-Aai can be used for content determination, identification, and pharmacological experiments, etc.
Safety Information
Personal Protective Equipment
Gloves, eyeshields, N95 mask
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0